AVBP ArriVent BioPharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1868279 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-11.7%
TTM EPS YoY13.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-48.4%
ROA-45.5%
ROIC (approx.)-60.6%
Asset turnover—
Leverage & solvency
Liabilities / assets5.7%
Debt / equity0.00x
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-4.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $5.00M | — | — | — | — | — | — | — |
| R&D expense | $38.90M | $42.34M | $37.62M | $32.17M | $32.17M | $27.72M | $61.29M | $20.16M |
| SG&A expense | $9.48M | $10.35M | $8.49M | $6.65M | $6.15M | $5.90M | $5.48M | $3.54M |
| Operating income | -$43.38M | -$52.69M | -$46.11M | -$38.82M | -$38.32M | -$33.62M | -$66.77M | -$23.70M |
| Net income | -$40.31M | -$49.89M | -$43.32M | -$35.54M | -$34.98M | -$31.40M | -$64.39M | -$20.63M |
| EBITDA | -$44.03M | -$53.21M | -$46.67M | — | — | — | — | — |
| EPS (basic) | -0.81 | -1.05 | -0.96 | — | -0.83 | -0.90 | -1.90 | — |
| EPS (diluted) | -0.81 | -1.05 | -0.96 | — | -0.83 | -0.90 | -1.90 | — |
| Weighted avg. shares (diluted) | 49.53M | 47.61M | 45.07M | — | 41.91M | 35.01M | 33.90M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $113.58M | $154.68M | $62.10M | $45.54M | $112.67M | $112.77M | $49.87M | $74.29M |
| Short-term investments | $279.64M | $218.44M | $264.28M | $267.28M | $187.59M | $122.92M | $126.21M | $144.57M |
| Current assets | $416.62M | $394.17M | $348.70M | $332.90M | $321.22M | $250.15M | $185.78M | $226.98M |
| Total assets | $417.09M | $394.72M | $349.30M | $333.17M | $326.56M | $269.51M | $215.50M | $274.94M |
| Current liabilities | — | $27.84M | $25.00M | $25.95M | $21.56M | $19.64M | $12.95M | $17.27M |
| Total liabilities | $23.61M | $27.88M | $25.32M | $25.95M | $21.56M | $19.64M | $12.95M | $17.29M |
| Shareholders' equity | $393.48M | $366.84M | $323.98M | $307.22M | $305.00M | $249.87M | $202.54M | $257.65M |
| Shares outstanding | 51.21M | 48.32M | 45.31M | 42.45M | 40.85M | 37.49M | 34.04M | 33.71M |
| Cash flow statement | ||||||||
| Operating cash flow | -$40.71M | -$39.58M | -$41.89M | -$30.66M | -$35.80M | -$26.12M | -$68.01M | -$16.15M |
| Investing cash flow | -$60.65M | $46.07M | $3.58M | -$71.20M | -$50.76M | $13.91M | $36.82M | — |
| Financing cash flow | $60.26M | $86.09M | $54.87M | $34.73M | $86.47M | $75.11M | $6.76M | $55,000 |
| Depreciation & amortization | -$653,000 | -$515,000 | -$559,000 | — | — | — | — | — |
| Stock-based compensation | $6.88M | $6.67M | $5.49M | $3.22M | $3.72M | $3.31M | $2.27M | $952,000 |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.